科研之友
微信
新浪微博
Facebook
分享链接
摘要
This article reviews the core principals of cost-effectiveness and applies them to the rapidly evolving context of hepatitis C virus treatment in the United States. The article provides a foundation of evidence that hepatitis C virus treatment provides good economic value, even though it is expensive, and even when treating people who inject drugs who are at high risk for hepatitis C virus reinfection. The price of medications has decreased, but the high price continues to limit access to care. This wedge between cost-effectiveness and affordability stands front and center as one of the leading obstacles to elimination.
- 出版日期2018-6
